Compare YieldMax AMZN Option Income Strategy ETF (AMZY) vs Charles River Laboratories Intl. Inc (CRL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
YieldMax AMZN Option Income Strategy ETF vs Charles River Laboratories Intl. Inc — how do they compare? YieldMax AMZN Option Income Strategy ETF trades at $10.75, while Charles River Laboratories Intl. Inc trades at $232.9 (market cap $11.24B). The key difference: Charles River Laboratories Intl. Inc is trading nearer its 52-week high, YieldMax AMZN Option Income Strategy ETF nearer its low. Which is the better fit depends on your goals.
| AMZY | CRL | |
|---|---|---|
Sector | Income / Options Overlay | Health |
52-Week High | $16.61 | $233.60 |
52-Week Low | $10.26 | $145.57 |
Market Cap | — | $11.24B |
Enterprise Value | — | $14.11B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMZY trades at $10.78 with no significant daily movement, showing neutral technical signals overall. The ETF maintains a consistent weekly dividend distribution strategy, though recent analyst commentary highlights concerns about NAV erosion despite high yields. Technical indicators show mixed signals with bearish moving averages but neutral oscillators, while support and resistance levels cluster tightly around $10-11.
The outlook remains cautious as the synthetic option strategy delivers high income but exposes investors to amplified downside risk. While weekly distributions provide income appeal, total returns have lagged the underlying Amazon stock, creating sustainability concerns for long-term investors seeking both income and capital appreciation.
Charles River Laboratories (CRL) trades at $233.41, down slightly by 0.08% today, with a bullish technical signal supported by moving averages. The company shows strong operational cash flow of $737.65M for 2025 but faces profitability challenges with negative net income margin of -4.59% and ROE of -6.02%. Recent earnings have consistently beaten expectations, and analyst consensus remains strongly positive with 72% buy ratings.
CRL presents a mixed investment case: strong cash generation and strategic collaborations like the Lilly TuneLab partnership provide growth catalysts, but negative profitability metrics and high valuation ratios (P/E 684.85) pose risks. The stock's outlook depends on margin improvement and successful execution of recent business initiatives amid competitive pressures.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About YieldMax AMZN Option Income Strategy ETF
AMZY is an actively managed ETF that seeks to generate monthly income by selling call options on Amazon (AMZN) stock. It aims to provide high yield while maintaining exposure to the price movements of the e-commerce giant.
Read more on AMZY →About Charles River Laboratories Intl. Inc
Charles River Laboratories was founded in 1947 and is a leading provider of drug discovery and development services. The company's research model & services segment is the leading provider of animal models for laboratory testing, which breeds and delivers animal research models with specific genetic characteristics for preclinical studies around the world. The discovery & safety assessment segment includes services required to take a drug through the early development process, including discovery services. The manufacturing support segment includes microbial solutions, which provides in vitro (non-animal) testing products, biologics testing services, and avian vaccine services.
Read more on CRL →
